Drug Profile


Alternative Names: BTK Inhibitor PCI-32765; CRA-032765; IMBRUVICA; Imbruvica; Imuburubika; JNJ-54179060; PCI-32765

Latest Information Update: 14 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Celera Genomics Group
  • Developer Foundation GIMEMA; Genentech; Janssen; Janssen Biotech; Lymphoma Academic Research Organisation; National Cancer Institute (USA); Northwestern University; OHSU Knight Cancer Institute; Pharmacyclics; Sheba Medical Center; Singapore General Hospital; Stanford University Medical Center; University of California, Davis; University of Leeds
  • Class 2 ring heterocyclic compounds; Antineoplastics; Antirheumatics; Phenyl ethers; Piperidines; Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Emt protein-tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease; Chronic lymphocytic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; MALT lymphoma; Mantle-cell lymphoma; Waldenstrom's macroglobulinaemia
  • Registered Graft-versus-host disease
  • Phase III Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
  • Phase II/III Pancreatic cancer
  • Phase II Acute lymphoblastic leukaemia; Acute myeloid leukaemia; B cell lymphoma; CNS cancer; Hairy cell leukaemia; Multiple myeloma
  • Phase I/II Gastrointestinal cancer; Non-small cell lung cancer; Renal cell carcinoma; Urogenital cancer
  • Phase I Cancer; Solid tumours
  • Preclinical Breast cancer; Colorectal cancer; Lymphoma
  • Discontinued Rheumatoid arthritis; Seasonal allergic rhinitis

Most Recent Events

  • 02 Aug 2017 Registered for Graft-versus-host disease (Treatment-experienced) in USA (PO)
  • 20 Jul 2017 Janssen initiates enrolment in a phase I trial in Diffuse large B cell lymphoma (Combination therapy, Second-line therapy or greater, Late-stage disease) in USA (IV) (NCT03136497)
  • 14 Jul 2017 Icahn School of Medicine initiates enrolment in a phase I/II trial in Chronic lymphocytic leukaemia and Mantle cell lymphoma (Combination therapy, Second-line therapy or greater) in USA (PO) (NCT03153202)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top